Orgenesis (ORGS) Competitors $1.41 -0.10 (-6.56%) As of 11:58 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ORGS vs. INKT, COEP, SXTC, SCYX, NRSN, TPST, CARA, TENX, LSTA, and CYTHShould you be buying Orgenesis stock or one of its competitors? The main competitors of Orgenesis include MiNK Therapeutics (INKT), Coeptis Therapeutics (COEP), China SXT Pharmaceuticals (SXTC), SCYNEXIS (SCYX), NeuroSense Therapeutics (NRSN), Tempest Therapeutics (TPST), Cara Therapeutics (CARA), Tenax Therapeutics (TENX), Lisata Therapeutics (LSTA), and Cyclo Therapeutics (CYTH). These companies are all part of the "pharmaceutical products" industry. Orgenesis vs. Its Competitors MiNK Therapeutics Coeptis Therapeutics China SXT Pharmaceuticals SCYNEXIS NeuroSense Therapeutics Tempest Therapeutics Cara Therapeutics Tenax Therapeutics Lisata Therapeutics Cyclo Therapeutics Orgenesis (NASDAQ:ORGS) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings. Does the media prefer ORGS or INKT? In the previous week, MiNK Therapeutics had 1 more articles in the media than Orgenesis. MarketBeat recorded 1 mentions for MiNK Therapeutics and 0 mentions for Orgenesis. Orgenesis' average media sentiment score of 0.00 equaled MiNK Therapeutics'average media sentiment score. Company Overall Sentiment Orgenesis Neutral MiNK Therapeutics Neutral Which has more risk and volatility, ORGS or INKT? Orgenesis has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500. Comparatively, MiNK Therapeutics has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500. Do insiders and institutionals hold more shares of ORGS or INKT? 22.6% of Orgenesis shares are owned by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are owned by institutional investors. 5.7% of Orgenesis shares are owned by company insiders. Comparatively, 22.5% of MiNK Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is ORGS or INKT more profitable? MiNK Therapeutics has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Company Net Margins Return on Equity Return on Assets Orgenesis-3,827.81% N/A -130.18% MiNK Therapeutics N/A N/A -140.72% Which has stronger earnings and valuation, ORGS or INKT? MiNK Therapeutics has lower revenue, but higher earnings than Orgenesis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrgenesis$662K10.23-$55.36MN/AN/AMiNK TherapeuticsN/AN/A-$9.51M-$2.52-2.86 Do analysts prefer ORGS or INKT? MiNK Therapeutics has a consensus target price of $37.50, suggesting a potential upside of 420.83%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe MiNK Therapeutics is more favorable than Orgenesis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Orgenesis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00MiNK Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryMiNK Therapeutics beats Orgenesis on 7 of the 11 factors compared between the two stocks. Get Orgenesis News Delivered to You Automatically Sign up to receive the latest news and ratings for ORGS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORGS vs. The Competition Export to ExcelMetricOrgenesisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.77M$780.02M$5.47B$8.95BDividend YieldN/A4.84%5.25%4.06%P/E RatioN/A1.0927.0020.10Price / Sales10.23230.52435.75120.29Price / CashN/A23.4436.8257.86Price / Book-0.216.137.985.56Net Income-$55.36M-$27.85M$3.16B$248.40M7 Day Performance-7.78%2.14%3.69%6.04%1 Month Performance-23.73%8.33%2.91%7.69%1 Year PerformanceN/A8.62%34.30%20.97% Orgenesis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORGSOrgenesisN/A$1.41-6.6%N/AN/A$6.77M$662K0.00150Gap DownINKTMiNK Therapeutics2.6798 of 5 stars$7.34+5.2%$37.50+410.9%-20.9%$27.82MN/A-2.9130News CoverageGap UpCOEPCoeptis Therapeutics0.1959 of 5 stars$7.80+0.3%N/A+37.5%$27.34MN/A-1.342News CoverageSXTCChina SXT Pharmaceuticals0.1482 of 5 stars$1.73+0.6%N/A-79.7%$27.22M$1.82M0.0090News CoverageSCYXSCYNEXIS0.258 of 5 stars$0.67-2.4%N/A-62.1%$26.98M$3.75M-1.2060NRSNNeuroSense Therapeutics1.6923 of 5 stars$1.89-0.5%$14.00+640.7%+69.9%$25.97MN/A-3.5010TPSTTempest Therapeutics1.5558 of 5 stars$6.80-1.4%$30.00+341.2%-73.0%$25.41MN/A-0.3820CARACara Therapeutics0.338 of 5 starsN/AN/AN/A$24.33M$7.14M-0.2580Gap DownHigh Trading VolumeTENXTenax Therapeutics1.2571 of 5 stars$5.76-1.5%$17.50+203.8%+81.4%$24.27MN/A-2.329LSTALisata Therapeutics2.48 of 5 stars$2.90+3.6%$15.00+417.2%-29.3%$24.12M$1M-1.2630Gap DownCYTHCyclo TherapeuticsN/A$0.72flat$0.95+31.8%N/A$23.72M$870.73K-0.809 Related Companies and Tools Related Companies MiNK Therapeutics Alternatives Coeptis Therapeutics Alternatives China SXT Pharmaceuticals Alternatives SCYNEXIS Alternatives NeuroSense Therapeutics Alternatives Tempest Therapeutics Alternatives Cara Therapeutics Alternatives Tenax Therapeutics Alternatives Lisata Therapeutics Alternatives Cyclo Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORGS) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored$3,200 from your phone?No charts. No crypto. No stock picking. With just a regular brokerage app and Jeff Clark’s “Crossfire” meth...TradeSmith | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orgenesis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Orgenesis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
